Who is sponsoring NCT07034326?

NCT07034326 is sponsored by Kong Fanming.

What drugs are being tested in NCT07034326?

Interventions in NCT07034326: Electroacupuncture combined with immunotherapy, Zilongjin tablet combined with immunotherapy, Immunotherapy.

What condition does NCT07034326 study?

NCT07034326 studies Non-Small Cell Lung Cancer, Electroacupuncture, Immune Checkpoint Inhibitors.

Is NCT07034326 still recruiting?

NCT07034326 is currently recruiting now. Last updated 24 June 2025.

Last reviewed 2025-06-24 · How we verify

NCT07034326

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer

Recruiting now Phase 2, PHASE3 Last updated 24 June 2025

What this trial tests

Phase 2, PHASE3 trial testing Electroacupuncture combined with immunotherapy in Non-Small Cell Lung Cancer in 405 participants. Currently enrolling.

Timeline

1 January 2025

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	Kong Fanming
Phase	Phase 2, PHASE3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	405
Start date	1 January 2025
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	1 location across China

Drugs / interventions tested

Electroacupuncture combined with immunotherapy
Zilongjin tablet combined with immunotherapy — full drug profile →
Immunotherapy — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →
Electroacupuncture — all drugs for Electroacupuncture →
Immune Checkpoint Inhibitors — all drugs for Immune Checkpoint Inhibitors →

Sponsor

Kong Fanming — full company profile →

Who can join

Adults 18 to 80, any sex, with Non-Small Cell Lung Cancer or Electroacupuncture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Postoperative immunoadjuvant therapy has been proven to significantly reduce the risk of recurrence after resectable NSCLC, and has become a new standard of postoperative adjuvant therapy for stage II-III NSCLC. Immunotherapy faces challenges such as immune resistance, heterogeneity of biomarker expression, and limitation of immune-suitable population. How to reduce the rate of recurrence and metastasis after surgery, enhance the therapeutic effect of immunotherapy, and then prolong the survival period and improve the quality of life, has become an urgent problem facing the current clinical. Based on the standards of evidence-based medicine, this study for the first time carried out a large sample, multi-center, randomized parallel controlled clinical study to obtain high-quality clinical evidence of the effectiveness and safety of electro-acupuncture and Zilongjin tablet synergic treatment, and formed a standard treatment plan of traditional Chinese medicine.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Harmonizing yin and yang, remodeling the microenvironment: the adjuvant potential of Chinese herbal medicine in tumor immunotherapy.
Gao X, Han Y, Yang L, Fang H, et al · · 2026 · PMID 41959898 · DOI 10.3389/fonc.2026.1806602
Research progress on traditional Chinese medicine-assisted immune checkpoint inhibitors therapy for solid tumors.
Liu Z, Xie Y, He Y, Chen K, et al · · 2026 · PMID 41694353 · DOI 10.3389/fimmu.2026.1723860

Verify or expand the search:

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Kong Fanming trials

Trials by the same sponsor.

NCT07239661 — Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC · NA · recruiting
NCT07086300 — Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC · NA · recruiting
NCT06548711 — Effect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07034326 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kong Fanming
Last refreshed: 24 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07034326.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing